Mauna Kea Technologies Secures CE MDR Certification for Cellvizio Platform
Event summary
- Mauna Kea Technologies received CE MDR certification for its Cellvizio platform and associated probes on February 10, 2026.
- The certification was issued by GMED, a leading notified body in the medical device sector.
- The certification ensures long-term commercialization of Cellvizio within the European Union and countries recognizing the CE mark.
- The company plans to deploy new clinical applications and integrate AI solutions within the current regulatory framework.
The big picture
The CE MDR certification is a significant milestone for Mauna Kea Technologies, ensuring compliance with the strictest international criteria for safety and clinical performance. This certification is crucial for the company's strategic expansion in Europe, particularly in high-potential clinical areas. The certification also paves the way for future integration of AI solutions, aligning with broader industry trends towards digital health innovations.
What we're watching
- Regulatory Compliance
- How the CE MDR certification will facilitate Mauna Kea Technologies' European commercial expansion.
- Market Expansion
- Whether the certification will accelerate adoption in pancreatic cysts and food intolerances (CellTolerance).
- Technological Integration
- The pace at which AI solutions will be integrated into the Cellvizio platform under the new regulatory framework.
Related topics